Myriad Genetics
MYGN
252 hedge funds and large institutions have $2.5B invested in Myriad Genetics in 2016 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 91 increasing their positions, 83 reducing their positions, and 25 closing their positions.
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
8% more funds holding
Funds holding: 233 → 252 (+19)
10% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 83
18% less capital invested
Capital invested by funds: $3.05B → $2.5B (-$544M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
67% less call options, than puts
Call options by funds: $8.7M | Put options by funds: $26.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$27M |
| 2 |
Morgan Stanley
New York
|
+$21.6M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$18.3M |
| 4 |
Millennium Management
New York
|
+$17.1M |
| 5 |
RRAM
River Road Asset Management
Louisville,
Kentucky
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
-$81.5M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$44.9M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$39.6M |
| 4 |
SCM
Scopia Capital Management
New York
|
-$26M |
| 5 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
-$17.2M |
MYGN Hedge Fund Activity: Q2 2016 in Review
252 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2016, worth a combined $2.5B — down 18% from $3.05B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new MYGN positions and 25 closed out — a net gain of 21 holders — while 91 added to existing stakes and 83 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $27M. The largest seller was RS Investment Management, exiting entirely with an estimated $81.5M sold.
- 252 institutional investors held Myriad Genetics (MYGN) as of Q2 2016, up from 233 in Q1 2016.
- Funds reported $2.5B of Myriad Genetics stock for Q2 2016, down 18% quarter-over-quarter.
- 46 funds opened new Myriad Genetics positions in Q2 2016 and 25 closed out, a net change of +21 holders.
- The largest Myriad Genetics buyer in Q2 2016 was Goldman Sachs, an estimated $27M added.
- The largest Myriad Genetics seller in Q2 2016 was RS Investment Management, an estimated $81.5M sold.
Based on aggregated 13F filings for Q2 2016.